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Influence of glaucoma surgery on visual function: a
clinical cohort study and meta-analysis
Francisco G. Junoy Montolio, Rogier P.H.M. M€uskens and Nomdo M. Jansonius
Department of Ophthalmology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
ABSTRACT.
Purpose: To determine the cost (loss of visual function associated with the
procedure) and benefit (long-term preservation of the visual field) of glaucoma
surgery.
Methods: We included 100 patients who underwent glaucoma surgery (Baerveldt
glaucoma implant [BGI], n = 61; trabeculectomy [TE], n = 39). Preoperatively,
the median (interquartile range [IQR]) standard automated perimetry mean
deviation (MD) was 12 (16 to 6) dB. We analysed the change in visual
acuity (BCVA) and MD due to the procedure and, in a subset with at least
5 years of perimetric follow-up both pre- and postoperatively (n = 20), the
change in rate of progression (ROP; time rate of change in MD). For the
surgery-induced change in ROP, we also performed a meta-analysis including
the current and previously published studies. From the surgery-induced decrease
in MD and change in ROP, we calculated the average postoperative duration
needed for the benefit to surpass the cost.
Results: Mean (standard deviation) MD decline was 1.3 (2.7) and 1.0 (2.3) dB
for BGI (p < 0.001) and TE (p = 0.009), respectively; no significant surgery-
induced changes in BCVA were found (p = 0.08 and p = 0.12, respectively). In
our study, surgery was associated with a non-significant deceleration of ROP
(from 0.37 [0.52] to 0.15 [0.48] dB/year; p = 0.23). The meta-analysis, based
on eight studies, showed an overall surgery-induced change in ROP of 0.44 (95%
confidence interval 0.25 to 0.64; p < 0.0001) dB/year.
Conclusion: Glaucoma surgery significantly reduces the progression velocity in
glaucoma. On average, the benefit of glaucoma surgery surpasses the cost after
approximately 1.5 years.
Key words: Baerveldt glaucoma implant – glaucoma drainage device – perimetry – progres-
sion – rate of progression – trabeculectomy
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Introduction
Glaucoma is one of the leading causes
of avoidable blindness, characterized
by a degeneration of the optic nerve
and corresponding visual ﬁeld loss. To
slow down this chronic, progressive eye
disease, treatment is focused on the
lowering of the intraocular pressure
(IOP) by restricting the production of
aqueous or by increasing its outﬂow.
The initial approach to achieve a lower
IOP is the daily use of IOP-lowering
drugs and/or one or more laser
treatments. Surgery is generally con-
sidered after impermissible progression
of visual ﬁeld loss despite maximal
tolerable medical and laser treatment.
Glaucoma surgery is not without risk
and may in itself compromise visual
function. It is a clinical challenge to
weigh the risk and beneﬁt in individual
patients.
Within glaucoma surgery, the cre-
ation of a ﬁstula (ﬁltering surgery) or
implanting a drainage system has
earned their spurs. Although invented
in the same time period, ﬁltering
surgery (trabeculectomy; TE) was the
ﬁrst surgical choice for decades. Nowa-
days, the popularity of glaucoma drai-
nage devices is growing (Gedde et al.
2012; Arora et al. 2015; Islamaj et al.
2018). The success of surgery might
come with a cost; however, as patients
often complain of a decrease in visual
function after surgery. This observa-
tion gives the clinician the sense of a
drawback of surgery. However, the
literature showed all three possible
outcomes: an improvement in visual
function, a decline and no eﬀect (Hagi-
wara et al. 2000; Sehi et al. 2010;
Balekudaru et al. 2014; Caprioli et al.
2016). The crucial question is, if there is
a surgery-induced loss, if it counterbal-
ances the loss avoided due to the IOP
lowering. The IOP lowering aims to
yield a lower rate of progression
(ROP), that is, a less negative time rate
of change in the standard automated
perimetry (SAP) mean deviation (MD)
– thus delaying blindness.
The aim of this study was to deter-
mine the cost and beneﬁt of glaucoma
surgery regarding visual function. For
this purpose, we analysed the change in
visual acuity and SAP MD due to the
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procedure (the cost) and the change in
rate of progression (ROP), that is the
time rate of change in the MD (the
beneﬁt). These analyses were per-
formed primarily in the cohort of the
Groningen Longitudinal Glaucoma
Study (GLGS; Heeg et al. 2005). For
the surgery-induced change in ROP, we
also performed a meta-analysis includ-
ing the current and previously pub-
lished studies. From the surgery-
induced decrease in MD and change
in ROP, we calculated the average
postoperative duration needed for the
beneﬁt to surpass the cost.
Materials and Methods
Study population and data acquisition
The present study is part of the GLGS,
a prospective observational cohort
study performed in a clinical setting.
The GLGS started in 2000 and is still
ongoing. The ethics board of the
University Medical Center Groningen
(UMCG) approved that for the current
study no informed consent had to be
obtained because the study comprised
a retrospective anonymous analysis of
ophthalmic examination and visual
ﬁeld data collected during regular glau-
coma care. The study followed the
tenets of the Declaration of Helsinki.
The subpopulation selected for the
present study consisted of patients who
were treated with a Baerveldt glaucoma
implant (BGI) or TE and who had at
least (1) two (not including the ﬁrst
visual ﬁeld, which was discarded
because of learning eﬀects) reliable
visual ﬁelds (measured with SAP
[Humphrey Field Analyzer 30-2 SITA
fast; Carl Zeiss, Jena, Germany]) both
pre- and post-intervention and (2) a
follow-up of at least one year after the
intervention, in the operated eye. If
both eyes met the inclusion criteria, a
random eye was chosen (based on even
or uneven case number in the data-
base). For the analysis concerning the
ROP, a perimetric follow-up of at least
ﬁve years was required both pre- and
post-intervention (Jansonius 2010;
Junoy Montolio et al. 2012). Visual
ﬁelds had to be reliable. A test result
was considered unreliable if false pos-
itives exceeded 10% or if both false
negatives and ﬁxation losses exceeded
10% and 20%, respectively. We pooled
false negatives and ﬁxation losses
because they were reported to have a
much smaller inﬂuence on the MD
(Junoy Montolio et al. 2012) and espe-
cially the false negative are not infor-
mative in glaucoma (Bengtsson & Heijl
2000). Both primary and secondary
glaucoma was allowed. We included
both phakic and pseudophakic
patients; patients who underwent a
cataract extraction simultaneously with
the glaucoma surgery were excluded.
We also excluded patients who under-
went a second glaucoma operation
during follow-up.
Surgical procedure
Indication for surgery and method
(BGI or TE) was made by either of
the two authors who also performed
the operations (RM and NJ). In gen-
eral, in our hospital, surgery is delayed
until we observe progression too rapid
for the age of the patient (Wesselink
et al. 2011), with maximum tolerable
medical treatment and after consider-
ing or performing laser surgery. Early
surgery is considered in cases with high
baseline IOP and limited IOP lowering
on non-surgical treatment, especially in
young patients with already moderate
or severe glaucoma at the time of
diagnosis. Trabeculectomy (TE) is the
ﬁrst choice in primary glaucoma in
phakic eyes with a clear lens; during the
last decade we moved from TE to BGI
in pseudophakic eyes. Baerveldt glau-
coma implant (BGI) is the ﬁrst choice
in secondary glaucoma.
Baerveldt glaucoma implant
A BGI with 350 mm2 plate was
implanted in the superior-temporal
quadrant. The tube was closed with a
vicryl 7-0 suture to restrict short-term
excessive drainage before encapsula-
tion. The tube was placed in the ante-
rior chamber through a peripheral
iridotomy made with the 23 G needle
used to create a scleral entry for the
tube, aiming at a position of the tube as
close to the iris as possible to prevent
endothelial cell loss (Tan et al. 2017).
For this, the anterior chamber was
temporary deepened with an air bubble
and the needle entered the eye 3 mm
posterior to the limbus, in parallel with
the iris plane. The tube entrance was
covered with a patch of donor sclera.
Intraocular pressure (IOP)-lowering
drugs were continued unchanged until
tube opening (typically six weeks after
the intervention) and then tapered
depending on the IOP. As of 2009,
some patients got a drainage suture for
early IOP reduction (Rietveld et al.
2009; van Hoefen Wijsard et al.
2018). Antibiotic drops were given for
two weeks (chloramphenicol 0.4%
three times a day); steroids for
10 weeks (dexamethasone 0.1% three
times a day for eight weeks followed by
two times a day for two weeks).
Trabeculectomy
A TE with fornix-based conjunctival
ﬂap and limbus-based scleral ﬂap was
performed superiorly with the applica-
tion of mitomycin C (0.2 mg/ml during
2–4 min; applied before making the
scleral ﬂap). The scleral ﬂap was
sutured with two or three nylon 10-0
sutures, with the possibility for laser
suture lysis afterwards. Conjunctiva
was closed with two or three vicryl 7-
0 sutures. Antibiotic drops were given
for two weeks (chloramphenicol 0.4%
three times a day); steroids for
12 weeks (dexamethasone 0.1% six
times a day for six weeks followed by
four times a day for four weeks and
ﬁnally two times a day for two weeks;
oral prednisone 30 mg for 10 days was
added if the inﬂammation was above
average in the early postoperative
phase).
Statistical analysis
As most of the characteristics of the
study population were not normally
distributed (according to the Shapiro–
Wilk test), we used nonparametric
descriptive statistics (median with
interquartile range [IQR]) to describe
the study population. Groups were
compared using a Mann–Whitney test;
for paired data, we used a Wilcoxon
test. Proportions were compared with a
chi-squared test. For pre-intervention
and post-intervention visual acuity,
IOP and the number of IOP-lowering
medications, we took the last value
before the intervention and a value
measured as close as possible to 1 year
after the operation; for MD, we took
the average value of the last two tests
before the intervention and the ﬁrst
two tests after the intervention. Inevi-
tably, a perimetric gap exists because of
a waiting list before the intervention
and delayed testing after the interven-
tion (until full recovery or a situation
deemed stable was reached). Hence, the
observed MD decline is a composite of
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a surgery-induced decline and a decline
due to intrinsic disease progression
during this perimetric gap (see Discus-
sion section). Rate of progression
(ROP) was determined using linear
regression. Changes (post-intervention
minus pre-intervention) were evaluated
with a paired t-test or Wilcoxon test,
depending on the distribution of the
paired changes. Similarly, we used
Pearson or Spearman correlation coef-
ﬁcients depending on the distribution
of the concerning variables. A p value
of 0.05 or less was considered statisti-
cally signiﬁcant.
Meta-analysis
For the meta-analysis, we included
glaucoma surgery studies regarding
either BGI or TE that reported on
preoperative and postoperative ROP of
MD based on a mean follow-up of at
least 3 years with SAP. Studies also
had to report a paired comparison of
the change in ROP with standard error,
conﬁdence interval, standard deviation
or p value. We searched for literature
in PubMed with search string ‘(glau-
com*) AND ((shunt OR tube) OR
(trabeculect*) OR surgery) AND
((Visual ﬁeld OR HFA OR perimetr*))
AND (progression OR (Rate of pro-
gression))’ and in Embase. Addition-
ally, we searched through the reference
list of the identiﬁed articles. The search
was performed in June 2017.
We calculated the mean of the
change in ROP using a random-eﬀects
model (DerSimonian & Laird 1986). If
the standard error of the change (or
conﬁdence interval or standard devia-
tion) was not provided, it was calcu-
lated from the reported p value; if no
exact p value was given, we used the
upper limit (for example, 0.05 in case of
p < 0.05), yielding a conservative esti-
mate of the standard error (Fu et al.
2013). We used a random-eﬀects model
because we expected signiﬁcant hetero-
geneity amongst the included studies
(indication of surgery, type of surgery,
cataract extraction during follow-up,
disease stage, postoperative care, eth-
nicity, etc.). Heterogeneity was evalu-
ated using the I2 statistic (Higgins et al.
2003). I2 is the percentage of the total
variation across the studies, that is
due to heterogeneity. Values up to
25%, 25–49%, 50–74% and 75% and
above are considered no, low, moder-
ate and high heterogeneity, respectively
(Higgins & Thompson 2002). We per-
formed a sensitivity analysis to evalu-
ate the contribution of each individual
study to the heterogeneity by sequen-
tially leaving out one study and re-
analysing the pooled estimate for the
remaining studies (Tobias 1999). Publi-
cation bias was assessed with Egger’s
regression asymmetry test (Egger et al.
1997) and Begg’s adjusted rank corre-
lation test (Begg & Mazumdar 1994).
Results
Table 1 presents the general character-
istics of the study population. As can
be seen in this Table, 61 patients
received a BGI and 39 a TE. For only
20 (11 BGI and 9 TE) patients, we had
a suﬃciently long follow-up duration
(at least 5 years both pre- and postop-
eratively) to compare ROP pre- versus
postoperatively, and for that reason,
we pooled BGI and TE for this anal-
ysis. Baerveldt glaucoma implant
(BGI) and TE patients were compara-
ble in age at surgery and gender.
Preoperatively, the BGI patients had
a lower BCVA (p = 0.043), a slightly
higher IOP (p = 0.027), and a similar
MD (p = 0.92), compared to the TE
patients. Pre- compared to postopera-
tively, both the BGI and the TE
patients had a signiﬁcantly lower IOP
with less medication (p < 0.001).
Figure 1 shows the change in BCVA
as a function of preoperative visual ﬁeld
loss. No signiﬁcant correlations were
found (p = 0.92 and p = 0.55 for BGI
and TE, respectively). A non-signiﬁcant
mean (SD) increase in logMAR BCVA
(i.e. a decrease in decimal BCVA)of 0.03
(0.14) was found for BGI (p = 0.08) and
of 0.04 (0.14) for TE (p = 0.12).
Figure 2 illustrates the surgery-
induced visual ﬁeld change as a func-
tion of preoperative visual ﬁeld loss.
Again, no signiﬁcant correlations were
found (p = 0.19 and p = 0.57 for BGI
and TE, respectively). A signiﬁcant
mean (SD) MD decline of 1.3 (2.7)
dB was found for BGI (p < 0.001) and
of 1.0 (2.3) dB for TE (p = 0.009). Of
the 61 patients with a BGI, 18 had
received a drainage suture for early
IOP reduction. Mean deviation (MD)
decline was 1.4 dB (p = 0.004) without
drainage suture and 1.1 dB (p = 0.025)
with drainage suture. The decline did
not diﬀer between the subgroups
(p = 0.73). The midpoint of the last
two preoperative visual ﬁelds was
6 months before surgery; the midpoint
of the ﬁrst two postoperative visual
ﬁelds was 1.5 years after surgery.
For the longitudinal analysis, the
median (IQR) follow-up was 7.0 (5.7–
8.8) years preoperatively and 7.6 (6.3–
9.3) years postoperatively. The mean
(SD) preoperative rate of progression
was 0.37 (0.52) dB/year. After sur-
gery, this was 0.15 (0.48) dB/year; the
paired diﬀerence (standard error) was
0.22 (0.18) dB/year (p = 0.23). Of the
20 patients with a longitudinal follow-
up, 4 (3 BGI, 1 TE) underwent a
cataract extraction before the glaucoma
surgery and 4 (2 BGI, 2 TE) after the
surgery. Exclusion of these patients
would result in a mean pre-op ROP of
0.37 dB/year and a mean post-op
ROP of 0.24 dB/year (to be com-
pared to 0.37 and 0.15 dB/year in
Table 2). Hence, the bias seems limited.
Table 1. General characteristics of the study population
BGI (n = 61) TE (n = 39) p†
Age [year; median (IQR)] 70 (57–75) 68 (59–73) 0.60
Gender (% female) 53 51 0.91
Visual acuity pre-op [logMAR, median (IQR)] 0.14 (0.02–0.28) 0.10 (0.00–0.17) 0.043
IOP pre-op [mmHg; median (IQR)] 21 (17–25) 18 (15–21) 0.027
IOP post-op [mmHg; median (IQR)] 13 (11–16) 13 (9–15) 0.40
Pre-op number of IOP-lowering
medications [median (IQR)]
3 (2–4) 3 (2–4) 0.68
Post-op number of IOP-lowering
medications [median (IQR)]
2 (1–3) 0 (0–0) <0.001
Pre-op mean deviation [dB; median (IQR)] 12 (16 to 6) 11 (16 to 7) 0.92
Pseudophakic (%)* 54.1 10.3 <0.001
Secondary glaucoma (%) 23.0 5.1 0.035
BGI = Baerveldt glaucoma implant; dB = decibels; IOP = intraocular pressure; IQR = interquar-
tile range; TE = trabeculectomy.
*Before surgery
†Mann–Whitney test for medians, chi-squared test for proportions.
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Complications for patients receiving
BGI (n = 61) included ptosis (n = 2),
persistent (i.e. orthoptic consultation
was warranted) diplopia (n = 1), and
additional surgery (cyclodiode laser
therapy; n = 1). Trabeculectomy (TE)
(n = 39) associated complications were
persistent bleb leakage (that is, bleb
leakage requiring surgical repair;
n = 2), failure (i.e. no visible bleb in
combination with a higher than desired
IOP; n = 2), hypotony with choroidal
detachment closer than two disc diam-
eters from the optic disc (n = 1), and
hypotony associated maculopathy
(n = 1; Abbas et al. 2018).
Table 2 shows the characteristics of
the studies included in the meta-analy-
sis. Eight studies were included, of
which one (Bhardwaj et al. 2013)
reported two subgroups. All but two
(Folgar et al. 2010; this study) included
only TE. Figure 3 shows the preoper-
ative and postoperative ROP with
standard error. As can be seen in this
ﬁgure, there was a wide variety in ROP
preoperatively but not postoperatively
(see Discussion section). The weighted
mean (95% CI) surgery-induced
change in ROP was 0.44 (0.25–0.64;
p < 0.0001) dB/year, indicating that
glaucoma surgery results in a signiﬁ-
cant deceleration of the ROP. I2 was
47%, that is, the studies showed a low
heterogeneity. Sensitivity analysis
showed that one of the subgroups of
the study of Bhardwaj et al. (2013)
substantially inﬂuenced the pooled esti-
mate. After excluding this study, the
overall eﬀect size was 0.45 (95% CI
0.32–0.57; p < 0.0001) dB/year with a
remaining I2 of 34%. There was no
evidence of publication bias (Egger’s
test: p = 0.48; Begg’s test: p = 0.30).
Discussion
In our study, both TE and BGI were
associated with a small but signiﬁcant
MD loss; no surgery-induced changes
in BCVA were found. Surgery was
Fig. 1. Surgery-induced change in best-corrected visual acuity (BCVA) as a function of
preoperative visual ﬁeld loss.
Fig. 2. Surgery-induced change in visual ﬁeld mean deviation (MD) as a function of preoperative
visual ﬁeld loss.











[mean (SE); dB/year]* p
Folgar et al. (2010) 28 3.6/3.5 1.48 (1.4) 0.43 (0.8) 1.05 (0.41) 0.01
Bhardwaj et al. (2013;
pre-op progressors)
9 5.8/4.5 1.0 (0.9) 0.2 (0.38) 0.80 (0.34) 0.02
Bhardwaj et al. (2013;
pre-op non-progressors)
8 5.8/4.5 0.1 (0.8) 0.2 (0.4) 0.30 (0.35) 0.40
Bertrand et al. (2014) 52 3.8/3.9 0.36 (0.79) 0.16 (0.58) 0.20 (0.14) 0.15
Mataki et al. (2014) 34 4.6/5.7 0.70 (0.52) 0.25 (0.50) 0.45 (0.11) <0.001
Caprioli et al. (2016) 74 5.1/5.4 0.7 (1.1) 0.1 (0.8) 0.60 (0.18) <0.001
Iverson et al. (2016) 9 7.6/5.4 1.05 (0.66) 0.25 (0.86) 0.80 (0.41) 0.05
Oie et al. (2017) 17 5.9/15.6 0.86 (0.51) 0.19 (0.2) 0.67 (0.20) <0.001
Junoy Montolio et al. 20 7.0/7.6 0.37 (0.52) 0.15 (0.48) 0.22 (0.18) 0.23
ROP = rate of progression; SD = standard deviation; SE = standard error.
*Estimated SE in case of non-exact p value.
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associated with a non-signiﬁcant decel-
eration of the ROP. In the meta-
analysis, based on eight studies, the
overall eﬀect size indicated that glau-
coma surgery signiﬁcantly reduces the
progression velocity in glaucoma.
Several studies reported an
unchanged BCVA after glaucoma sur-
gery, for both TE (Bevin et al. 2008;
Bhardwaj et al. 2013; Balekudaru et al.
2014; Bertrand et al. 2014; Iverson et al.
2016) and BGI (Namavari et al. 2016),
and in a recent randomized clinical trial
(RCT) comparing primary BGIwith TE
(Islamaj et al. 2018). This is in agree-
ment with our results. Only a few studies
described BCVA loss after surgery
(Gedde et al. 2007; Stead & King 2010;
Christakis et al. 2017). Stead & King
(2010) found, in patients with very
severe glaucoma (mean [SD] MD
25.3 [3.5] dB) who underwent a TE,
that nine of 104 patients lost two lines of
Snellen or more – deemed to be related
to glaucoma – at the end of the follow-
up (i.e. on average three years postop-
eratively). In the multicentre RCT of
Gedde et al. (2007) comparingBGIwith
TE, the BCVA decreased signiﬁcantly,
on average (SD) from 0.43 (0.54) and
0.37 (0.38) logMAR preoperatively to
0.61 (0.75) and 0.49 (0.56) after one year
for the BGI and TE patients, respec-
tively. The authors described that the
main reasons for the loss of BCVAwere
cataract and other, not glaucoma-
related, reasons. Christakis et al.
(2017) found in their multicentre RCT
comparing Ahmed drainage devices
with BGI a mean (SD) decrease in
BCVA from 1.1 (1.0) to 1.3 (1.2)
logMAR in BGI patients after one year.
They described that 34% of the patients
lost two or more lines of Snellen, of
which 18% was caused by glaucoma,
15% by cataract and 68% by macular
disease or other causes. Harju et al.
(2018) studied the long-term results of
deep sclerectomy. Four of 37 patients
had a VA loss of two lines or more; in
two cases this was attributed to cataract
formation. The main diﬀerence between
these four studies and our study is the
much higher preoperative BCVA in our
study (Table 1). This suggests that a low
preoperative visual acuity is an indicator
of further surgery-induced loss, a plau-
sible hypothesis from a clinical point of
view. The limited variability in our
preoperative BCVA preludes a detailed
check of this hypothesis in our data.
Development of cataract could be an
issue, as progression of cataract is found
within 1 year after surgery, particularly
in eyes with postoperative complica-
tions (Gedde et al. 2007). However, this
seemed not to be the case in our data.
Subgroup analysis comparing patients
who were pseudophakic before surgery
with patients who were phakic did not
reveal any diﬀerence in visual acuity
change, neither in the BGI group nor in
the TE group.
Only a few earlier studies reported on
a surgery-induced MD decline. Most
studies found no inﬂuence on the MD
(Tavares et al. 2006; Sehi et al. 2010;
Yamazaki & Hayamizu 2012; Baleku-
daru et al. 2014; Wright et al. 2015;
Islamaj et al. 2018); one study found a
deterioration of the MD after a TE
(Hagiwara et al. 2000). In the latter
study, the postoperative MD was
assessed at the end of the follow-up
(mean follow-up duration was
4.75 years). In most of the studies that
found no eﬀect, the authors compared
the ﬁrst visual ﬁeld after the operation
to the last visual ﬁeld before the oper-
ation; in two studies, they performed
two visual ﬁelds at the same time-point.
We reported a mean surgery-induced
MD decline of 1.3 and 1.0 dB for BGI
and TE, respectively. This decline was
based on the last two tests before the
intervention and the ﬁrst two tests after
the intervention. This method was cho-
sen to reduce variability and to com-
pensate for a possible regression to the
mean eﬀect: a poor VF could trigger the
clinician to initiate surgery and consid-
ering only this ﬁeld could thus mask
surgery-induced damage. By using four
visual ﬁelds, however, a part of the
observed decline will actually be caused
by progression that would have
occurred anyway – the ﬁelds were not
clustered (as would have been done in a
trial) but made as part routine clinical
care. This is illustrated in Fig. 4. If we
assume an observed surgery-induced
MD decline of 1.2 dB, an interval of
two years between the time-point half-
way the last two tests before the inter-
vention and the time-point halfway the
ﬁrst two tests after the intervention
(0.5 years before the intervention and
1.5 years after the intervention; based
on our 61 + 39 interventions), and a
ROP of0.63 dB/year before the inter-
vention and 0.19 dB/year after the
intervention (inverse-variance estimates
based on the meta-analysis), then 50%
(0.5*0.63 + 1.5 + 0.19 = 0.6 of 1.2 dB)
of the observed decline could be attrib-
uted to the perioperative perimetric gap
and the other 50% to the surgery itself.
In our study, glaucoma surgery
yielded a non-signiﬁcant deceleration
of the ROP. The non-signiﬁcance could
be related to the small sample size and/
or remaining variability in the ROP
estimate in individual patients – despite
a relatively long follow-up duration, or
may actually denote no eﬀect. The
small sample size was related to the
exclusion of combined surgery (glau-
coma surgery and cataract extraction
simultaneously; see next paragraph)
and the required long follow-up dura-
tion; in our tertiary referral centre,
most glaucoma surgeries are performed
on patients with secondary glaucoma
(De Vries et al. 2016) and on referred




patients. Both groups often lack an
uninterrupted perimetric follow-up.
We conﬁned the current study to the
regular visitors of our department, for
whom we collect observational data
prospectively as of 2000 – as part of the
GLGS. Interestingly, all identiﬁed pub-
lished studies that reported on ROP
before and after glaucoma surgery
pointed in the same – beneﬁcial –
direction, but the change in ROP was
not always statistically signiﬁcant. The
overall eﬀect size of the meta-analysis,
however, was highly signiﬁcant, indi-
cating the value of meta-analysis as a
statistical tool to provide a solid
ground for performing surgery.
We excluded patients who under-
went a cataract extraction simultane-
ously with the glaucoma surgery but we
did not exclude those who underwent a
cataract extraction during the longitu-
dinal follow-up. Both inclusion and
exclusion of patients who underwent a
cataract extraction during the longitu-
dinal follow-up could induce bias. As
shown in the Results section, this bias
seems limited in this population.
Before the operation, the mean ROP
varied largely between the studies. This
might reﬂect, amongst others, diﬀer-
ences in policy regarding indicating
surgery. After the operation, the mean
ROP was close to 0.2 dB/year in
most of the studies (Table 2, Fig. 3).
Interestingly, a value of 0.2 dB/year
is the typical mean value as reported in
several glaucoma cohorts (Heijl et al.
2002; De Moraes et al. 2012; Wesselink
et al. 2012). This indicates that glau-
coma surgery is indeed able to bring
rapid progressors back into the normal
ROP range. Despite the preoperative
variability in ROP, the studies in the
meta-analysis showed a low hetero-
geneity. The majority of the hetero-
geneity could be attributed to the
subgroup of the study of Bhardwaj
et al. (2013) in which patients were
included without preoperative progres-
sion.
Limitations of this study were the
observational design of the GLGS and
the limited sample size in especially the
longitudinal part of the current study.
Reasons for the limited sample size
were given above; we addressed this by
performing a meta-analysis. By com-
bining many studies that showed not
always signiﬁcant results on their own,
we were able to determine the highly
signiﬁcant beneﬁt of glaucoma surgery.
The observational nature of the GLGS
implies that the patients included in the
current study may form a biased sam-
ple. In case of a real disaster, post-op
visual ﬁelds may be lacking, resulting
in exclusion and bias towards good
outcomes. On the other hand, visual
ﬁelds may also be taken less frequently
in cases with a well-regulated IOP (as
they are less urgent for clinical decision
making), yielding bias towards poor
outcomes. Clearly, an observational
study, and even not a meta-analysis of
observational studies, can beat a large
randomized clinical trial (RCT). How-
ever, RCTs performed in the ﬁeld of
glaucoma surgery thus far reported
only on IOP and visual ﬁeld change
deﬁned as a post-op progression event
(Ederer et al. 1994; Musch et al. 1999;
Anderson et al. 2003; Gedde et al.
2012); no RCT data regarding change
in ROP are available. We required a
follow-up of at least 5 years pre- and
postoperatively for our own longitudi-
nal analysis (see Methods section); we
had to weaken this to 3 years for the
meta-analysis (Table 2). With 3 years,
ROP assessment in individual patients
is still very noisy, as was argued by
modelling (Jansonius 2010) and shown
in patient data (Junoy Montolio et al.
2012; their table 3 shows that a short
follow-up causes a spurious widening
of the ROP distribution).
Glaucoma surgery could be an
ungrateful intervention to perform as
most patients have little complains
preoperatively, while experience the
perioperative and postoperative hassle
and possible visual acuity and visual
ﬁeld loss. Therefore, it is very impor-
tant to understand what patients relin-
quish to prevent future blindness.
Figure 4 illustrates the cost and ben-
eﬁt of glaucoma surgery, compiled
from our cost data (surgery-induced
MD decline) and the ROP results
from the studies included in the
meta-analysis. It shows that, on aver-
age 1.5 years after the operation (de-
picted as time-point 0 years in Fig. 4),
patients that were operated are better
oﬀ than patients who declined surgery
(crossing of continuous and dashed
line in Fig. 4). Note that the end of
the perimetric gap (right side of grey
bar) and the crossing of the lines
coincide coincidentally; this may give
the clinician, when restarting perime-
try after surgery, the spurious impres-
sion that the surgery did not have any
eﬀect. Figure 4 may also be used to
inform the patient properly, and it
illustrates that the decision to operate
is not always an easy one, but should
involve the weighing of, amongst
others, current damage, ROP, IOP
and life expectancy (Wesselink et al.
2011).
In conclusion, the cost of glaucoma
surgery is the loss of visual function
associated with the procedure; the
beneﬁt is the long-term preservation
Fig. 4. Schematic time–course of the visual ﬁeld mean deviation (MD) with (continuous line) and
without (dashed line) surgery. The surgery itself is performed at time-point 0 years. The surgery-
induced drop in MD is counterbalanced by the slower rate of progression, on average 1.5 years
after surgery (crossing of continuous and dashed line). The grey bar depicts the period in which no
perimetry is performed (from 6 months before to 1.5 years after surgery; see Results section). The
observed drop in MD, that is the diﬀerence in MD between the beginning and the end of the grey
bar, is about twice as large as the actual drop in MD, because of autonomous disease progression
in the period without perimetry.
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of the visual ﬁeld due to the reduced
rate of progression. Both are signiﬁ-
cant. On average, the beneﬁt of glau-
coma surgery surpasses the cost after
approximately 1.5 years.
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